The company, Vault Pharma, is working with UCLA and other universities to advance a vaccine with the potential to treat the virus in addition to protecting against it.
Vault Pharma was co-founded by Leonard H. Rome, distinguished professor of biological chemistry and associate director of the California NanoSystems Institute at UCLA, and is headquartered on campus at CNSI's Magnify incubator.
The business's activities are an example of how technologies that begin in academic labs are moved toward the market, where they can help the most people.
The Magnify incubator helps to advance nanoscience and technology-based startups by offering entrepreneurs laboratory and co-working space, as well as access to specialized UCLA research facilities, exactly what Vault Pharma needed.
Vault Pharma creates genetically modified versions of vaults, naturally occurring nanoparticles found inside every human cell. Measured in billionths of a meter, vaults were first discovered in the Rome Lab. While their innate function is not fully understood, Rome suspects vaults play a role in the immune system.
The barrel-shaped nanoparticles comprise a shell made of 78 copies of one particular protein, housing two additional proteins and some genetic material. Rome's team has re-engineered the vault as a delivery device, loading the interior with proteins for applications such as potential therapies or vaccines.
Already under development are vault-based therapies for diseases such as lung cancer and human papillomavirus.
Now, Vault Pharma and its collaborators are modifying the technology to vaccinate against the coronavirus.
Studies suggest that a vault-based vaccine could additionally work as a therapy. While the platform hasn't been tested in humans, proof-of-concept research indicates that vaults are non-inflammatory but are readily internalized by multiple immune cells, involved with both types of adaptive immunity --bodily defenses that respond to specific invaders.
As with typical vaccines, the vault-based strategy is meant to prevent infection by activating the humoral immune system, which uses antibodies to neutralise foreign microbes in bodily fluids and tag them for elimination by immune cells.
In this way, a vault-based vaccine might provoke a complete and balanced immune response.
Vault Pharma is designing their vaccine with the Rome Lab and the research teams led by Dr. Otto Yang, a professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA, and Jeff F. Miller, UCLA's Fred Kavli Professor of NanoSystems Sciences and the director of CNSI.
Candidate vaccines will be tested by Northern Arizona University's Todd French, assistant professor of biological sciences, who is developing animal models for studying coronavirus in NAU's COVID-19 Testing Service Center.
French is an expert in the mechanisms that make infectious microbes more dangerous.
Plans for manufacturing are in progress as well. Working with Mark Arbing, who directs the Fermentation Core Facility in the UCLA Molecular Biology Institute, the company and researchers have developed a method for prompting engineered yeast to produce custom-designed vaults.
For potential clinical trials, production of vaccine-laden vaults will be scaled up at the University of Nebraska–Lincoln Biological Process Development Facility, which manufactures engineered proteins and peptides, for research and clinical trials.
Foellmer and Rome caution that their approach is not a frontline defense. A vault-based coronavirus vaccine is intended to add to the armament against the disease after an initial vaccine has been developed and distributed, and could represent a step toward blocking a similar virus outbreak in the future.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002